

A provider's guide to helping patients afford Apri 28 Day, including ACA coverage, discount cards, patient assistance programs, and generic alternatives.
Medication adherence is one of the biggest challenges in contraceptive care. When patients can't afford their birth control, they skip doses, stretch packs, or stop altogether — all of which increase unintended pregnancy risk. As a prescriber, having a practical understanding of cost-saving options for Apri 28 Day (Desogestrel 0.15 mg / Ethinyl Estradiol 0.03 mg) allows you to proactively address affordability before it becomes an adherence problem.
This guide covers what your patients are actually paying, the savings programs available, and how to integrate cost conversations into your prescribing workflow.
Apri 28 Day is a generic combined oral contraceptive manufactured by Teva Pharmaceuticals. Here's the current cost landscape:
Under the ACA contraceptive mandate, most commercial insurance plans are required to cover at least one form of each FDA-approved contraceptive method at $0 cost-sharing. For generic oral contraceptives like Apri 28 Day, this means most insured patients should pay nothing out of pocket.
However, there are exceptions that can create unexpected costs:
Medicaid covers oral contraceptives in all 50 states, typically at $0.
For an uninsured patient filling monthly, that's a difference between $360-$1,188 per year at retail versus $120-$252 per year with a discount card — a meaningful savings that can determine whether a patient stays on their medication.
Since Apri 28 Day is already a generic product, Teva Pharmaceuticals does not offer a manufacturer copay card (these are typically reserved for brand-name products competing with generics). However, there are other manufacturer-adjacent options:
Teva's patient assistance program may cover eligible uninsured or underinsured patients who meet income requirements. Patients can apply through the Teva Cares Foundation. Eligibility typically requires:
As a provider, you can initiate the application process on behalf of your patient during the office visit, reducing the likelihood that they'll fall through the cracks.
Discount cards are the most accessible savings option for uninsured and underinsured patients. These are free, require no enrollment, and work at most pharmacies:
These cards cannot be combined with insurance. They work as an alternative to insurance pricing, not a supplement. For patients whose insurance copay exceeds the discount card price (which can happen with high-deductible plans), using the discount card instead of insurance may save them money.
For a comprehensive comparison, our patient-facing Apri 28 Day savings guide walks through all available options.
For patients who need more than a discount card — particularly those with no insurance and limited income — these organizations can help:
When availability or cost is a persistent issue, therapeutic substitution is a practical solution. As a prescriber, you have several equivalent or near-equivalent options:
These contain identical formulations to Apri 28 Day (desogestrel 0.15 mg / ethinyl estradiol 0.03 mg):
These are AB-rated generics — pharmacists can typically substitute between them without a new prescription, depending on state law and payer requirements. If a patient's plan covers Reclipsen but not Apri, switching is clinically straightforward.
If the patient needs a different formulation entirely:
For a full clinical comparison of alternatives, see our provider shortage guide and alternatives overview.
Cost conversations don't have to be lengthy or awkward. Here are practical ways to integrate affordability screening into contraceptive prescribing:
A simple "Are you having any trouble affording your medications?" or "Has the cost of your birth control changed recently?" can surface problems patients don't volunteer. Many patients silently ration or abandon medications rather than bring up cost.
For combined oral contraceptives, generics are clinically equivalent and dramatically more affordable. Unless a patient has a specific tolerability reason for a brand, default to generic prescribing.
Many states now require or allow pharmacists to dispense a full year's supply of oral contraceptives at once. Writing for 12 months (with appropriate refills) reduces pharmacy visits, reduces gaps in coverage, and improves adherence. It also avoids the recurring hassle of stock checks.
Have a simple handout or digital resource your staff can share with patients who report cost barriers. Include:
When patients can't find their specific generic in stock, Medfinder for Providers can help identify which pharmacies in the patient's area have Apri 28 Day available and at what price. This saves time for both your staff and your patients.
Noting cost-related adherence concerns in the patient's chart creates continuity. If a patient returns with breakthrough bleeding or an unplanned pregnancy, cost documentation provides important context for clinical decision-making.
Apri 28 Day is one of the most affordable oral contraceptives on the market — but "affordable" is relative. For uninsured patients, even $30/month can be a barrier. For insured patients, formulary nuances can create unexpected copays. The most effective contraceptive is one the patient can consistently access and afford.
By proactively addressing cost, prescribing generics, writing 12-month prescriptions, and knowing the savings resources available, you can meaningfully improve contraceptive adherence in your patient population.
For more clinical resources on Apri 28 Day, see our provider guide to finding Apri 28 Day in stock and the provider shortage update.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.